BiotechTube

5 Methoxy N,N Dimethyltryptamine

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Treatment Resistant Depression

Conditions

Treatment Resistant Depression, Major Depressive Disorder, Depression

Trial Timeline

Nov 12, 2019 → Nov 6, 2021

NCT ID
NCT04698603

About 5 Methoxy N,N Dimethyltryptamine

5 Methoxy N,N Dimethyltryptamine is a phase 1/2 stage product being developed by GH Research for Treatment Resistant Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT04698603. Target conditions include Treatment Resistant Depression, Major Depressive Disorder, Depression.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (3)

NCT IDPhaseStatus
NCT06511947Phase 1Recruiting
NCT04698603Phase 1/2Completed
NCT04640831Phase 1Completed

Competing Products

20 competing products in Treatment Resistant Depression

See all competitors
ProductCompanyStageHype Score
Olanzapine and Fluoxetine combination (OFC) + FluoxetineEli LillyPhase 3
77
Olanzapine + Fluoxetine + PlaceboEli LillyPhase 3
77
Hetrombopag Olamine + PlaceboJiangsu Hengrui MedicinePhase 3
77
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
77
Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 3
77
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
77
Irinotecan liposome、5-Fluorouracil、Leucovorin + Placebo、5-Fluorouracil、LeucovorinJiangsu Hengrui MedicinePhase 3
77
Dalpicilib + Abiraterone Acetate (II) + Androgen Deprivation Therapy + PrednisoneJiangsu Hengrui MedicinePhase 2
52
SHR8058 eye drops + saline eye drops.Jiangsu Hengrui MedicinePhase 3
77
Risankizumab + ComparatorAbbViePre-clinical
23
Chemotherapy + Cross-over to OsimertinibAstraZenecaPhase 3
77
AZD6765 + Placebo to AZD6765AstraZenecaPhase 2
52
TC-5214 + PlaceboAstraZenecaPhase 1
33
ACS patients treated with OAPAstraZenecaPre-clinical
23
AZD6738AstraZenecaPhase 1
33
MK-1942 + PlaceboMerckPhase 2
52
5-FU + Folinic Acid + Irinotecan + Cetuximab + AvelumabMerckPhase 2
52
simvastatin/ezetimibe + atorvastatin 20mgMerckApproved
85
BKM120NovartisPhase 2
52
LEE011NovartisPhase 2
52

Other Products from GH Research

GH001Phase 2
47
GH001Phase 2
47
GH001 + PlaceboPhase 2
47
5 Methoxy N,N Dimethyltryptamine + PlaceboPhase 1
28
5 Methoxy N,N Dimethyltryptamine + PlaceboPhase 1
28